Announcement • Jun 16
Oncolytics Biotech Inc. Secures New U.S. Patent Protecting Commercial Manufacturing Of Pelareorep Oncolytics Biotech Inc. announced that the United States Patent and Trademark Office has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep. The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044. The patent is designed to protect the Company’s ability to consistently produce pelareorep at commercial scale and represents a significant addition to Oncolytics’ growing intellectual property portfolio. The Company also announced that a previously filed method-of-use patent application directed at pelareorep’s use as an immunotherapy remains under review and, if issued, is expected to provide protection into the year 2046. In addition, Oncolytics plans to file further patent applications this year that are designed to expand and strengthen the pelareorep intellectual property estate across additional therapeutic applications, treatment settings, and combination approaches. The Company’s intellectual property strategy is focused on protecting pelareorep through a combination of manufacturing, method-of-use, formulation, and combination therapy patents designed to support the continued development and commercialization of pelareorep across multiple oncology indications. Pelareorep is an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors to “hot” through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. ONCY
Live News • Jun 03
Oncolytics Biotech Sees Early Promise in Pelareorep and RAS Inhibitor Solid Tumor Study Oncolytics Biotech reported early preclinical data showing that its lead asset pelareorep, when combined with RAS inhibitor therapies, produced stronger anti-tumor activity than either agent alone in solid tumor models.
The combination showed particular promise in aggressive RAS-mutated cancers such as pancreatic ductal adenocarcinoma and colorectal cancer, where current treatment options are limited.
The company plans to expand its work with pelareorep in combination with KRAS G12C and pan-RAS inhibitors, with full results from ongoing studies targeted for release in fall or winter 2026, alongside recent insider buying activity in the stock.
The key point is that pelareorep is being positioned as a potential immune priming backbone that could fit alongside multiple RAS inhibitor approaches in difficult solid tumors.
For you, the main consideration is the long lead time to fuller data and the usual execution and clinical risk around translating preclinical findings into meaningful human trial outcomes. Announcement • Jun 03
Oncolytics Biotech Inc. Announces Appointment of Stephen Glover as Director and Promotion of John Mcadory as Chief Operating Officer Oncolytics Biotech Inc. announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. Mr. McAdory, age 49, has been appointed Chief Operating Officer of the Company, effective June 1, 2026. Mr. McAdory previously served as Executive Vice President, Strategy and Operations of the Company from January 2026 to June 2026. From January 2020 to January 2026, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology Inc., where he led clinical operations through its pivotal Phase 3 program and initial public offering. From February 2018 to January 2020, Mr. McAdory served as Head of Clinical Operations at SillaJen Inc. Earlier in his career, Mr. McAdory held clinical operations positions at UCB and Amgen Inc. Mr. McAdory holds a Master of Health Administration from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Hampton University. As COO, he will oversee the Company’s clinical operations and development activities, preclinical research and development efforts, and will play a key role in strategic partnerships and broader business development initiatives. Mr. McAdory joined Oncolytics earlier this year after serving as VP of Clinical Operations at CG Oncology. Mr. Steve Glover, age 66, has more than 35 years of leadership experience in the biopharmaceutical and life sciences industries. Mr. Glover currently serves as Co-Founder, Chairman, Chief Executive Officer, and President of ZyVersa Therapeutics, which he led to a public listing in December 2022. He also serves as Chairman of the Board of Directors of PDS Biotechnology, a member of the Board of Directors of Biogene Therapeutics, and a board member of the Coulter Foundation at the University of Miami U Innovation Center. Previously, Mr. Glover served as Chairman of the Board of Directors of Ambrx Biopharma, where he helped guide the company through significant growth and its acquisition by Johnson & Johnson in a transaction valued at approximately $2 billion. Mr. Glover was also Co-Founder and Chief Business Officer of Coherus BioSciences, Prior to Coherus, he served as President of Insmed Therapeutic Proteins and Executive Vice President and Chief Business Officer of Insmed Incorporated. Earlier in his career, Mr. Glover held leadership positions of increasing responsibility at GSK, Roche, and Amgen. The Board believes that Mr.Glover’s extensive experience in executive roles and public company board positions in the pharmaceutical and biotech industries qualifies him to serve as a Board member. 
